Prospective Cohort for Early Detection of Liver Cancer

Inclusion Criteria: 1. Patients of all genders, age \>18 years 2. Participant is willing and able to give informed consent for participation in the study. 3. Evidence of cirrhosis CP A or B (as defined below, cirrhosis ever diagnosed), with an underlying aetiology of at least one of the following: chronic Hepatitis B Virus (HBV) infection, chronic Hepatitis C Virus (HCV) infection, alcoholic liver disease, non-alcoholic fatty liver disease or haemochromatosis Cirrhosis Diagnosis Definition 1. Histological assessment (Ishak stage 5 or 6) or 2. At least one of the following: i. Validated non-invasive marker of fibrosis including fibroscan, AST to Platelet Ratio Index (APRI) score \>2 or Enhanced Liver Fibrosis (ELF) score \>10.48 or Fibrotest score \>0.73. Fibroscan readings should be assessed by aetiology as below: * HBV: \>=10 kPa * HCV: \>=14.5 kPa * Alcoholic Liver Disease (ALD): \>=19.5 kPa * Non-alcoholic fatty liver disease (NAFLD): \>=15 kPa * Haemochromatosis: \>=12kPa ii. Evidence of varices at endoscopy or imaging in the context of a patent portal vein iii. Definitive radiological evidence of cirrhosis (i.e. nodularity of liver and splenomegaly on Ultrasound/CT) Exclusion Criteria: 1. Diagnosis of current OR historical hepatocellular carcinoma 2. Liver transplant recipients or patients on active listing for liver transplantation 3. Child-Pugh C cirrhosis 4. In the view of the clinician, if the patient has a co-morbidity likely to lead to death within the following 12 months 5. In the view of the clinician, if the patient was not thought to be suitable for HCC surveillance